US Cosmetics Companies Doing Gap Analysis, Awaiting FDA Instruction In MoCRA’s First Year
Amin Talati Wasserman attorney Angela Diesch discusses the priorities, questions and concerns among companies facing end-of-year deadlines under the Modernization of Cosmetic Regulations Act enacted in the final days of 2022.
You may also be interested in...
Getting A Jump On MoCRA Compliance; Due Diligence Now Will Lighten Load, Risks Later
Cosmetics companies should not sit idly waiting for FDA to clarify new requirements under the Modernization of Cosmetic Regulations Act, speakers agreed at the Independent Beauty Association’s 2023 Technical/Regulatory Forum. Companies should be reviewing products, people and processes, including those of contract manufacturers, to get ahead of the curve.
Attorneys On Modernized Cosmetic Regulations And New Litigation Risks
Greenberg Traurig and Hogan Lovells attorneys provide first breakdowns of the game-changing Modernization of Cosmetic Regulations Act, including the potential for new lawsuits and plaintiff tactics.
Compliance Clock Starts Ticking Under Historic Modernization of Cosmetic Regulations Act
Companies have one year to comply with US FDA registration and product listing requirements under the Modernization of Cosmetic Regulations Act of 2022, part of the $1.7tr omnibus spending package signed by President Joe Biden on 29 December. Trade groups applauded the historic milestone and the legislation’s departure from previous proposals, including the elimination of user fees.